English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2511392      線上人數 : 167
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/63220


    題名: 台灣製藥朝藥品委託研究開發暨生產服務策略發展之個案分析-以保瑞藥業為例
    A Case Study of Strategy for the Contract Development and Manufacturing Organization Company in Taiwan: Taking Bora Pharmaceutical as an example
    作者: 陳冠志
    CHEN, KUAN-CHIH
    貢獻者: 管理學院生物科技高階管理碩士在職專班
    蕭育仁
    關鍵詞: 併購
    Contract Development and Manufacturing Organization(CDMO);Mergers and Acquisition
    日期: 2023-01-11
    上傳時間: 2023-12-07 09:59:48 (UTC+8)
    摘要: 保瑞藥業透過橫向與縱向的併購，堅持只購買賺錢的公司，同時以購買資產為 主外，並且確保該資產進入保瑞能賺錢，九年期間透過七次的併購案，前四次 著重在水平規模化的併購，後三次則是著重於垂直跨域化的併購，市值平均年 成長率達到 57%，營收從 2013 的 0.93 億到 2022 年第三季營收已經達到 52 億 元，營收成長 50 倍，同時淨利從 0.04 億元成長到 9.9 億元，保瑞藥業善用槓 桿收購(LBO)的方式以及 2021 年台新健康私募基金的投入，確保在資金無虞 的情況下，採用垂直延伸和橫向整合的混合策略，並且以利基技術作為其產業 發展策略，期在不同策略的應用下，在 CDMO(Contract Development and Manufacturing Organization)產業占有一席之地，同時持續配合客戶研發策略、 提高自身生產能力及不斷開發新型技術的耕耘下，CDMO 因為具有解決問題 能力、創新能力和反應速度，逐步由從 CDMO 再拓展到 CRDMO（委託研究、 開發與生產）一條龍佈局，正在成為製藥產業鏈中真正延伸且不可或缺的一部分。
    Through horizontal and vertical mergers and acquisitions, Paul Y. Pharmaceuticals insists on buying only profitable companies, and at the same time focuses on buying assets to ensure that the assets will be profitable when they enter Paul Y. Pharmaceuticals has made seven mergers and acquisitions during the nine-year period, with the first four focusing on horizontal scale mergers and acquisitions, and the last three focusing on vertical cross-domain mergers and acquisitions, with an average annual growth rate of 57% in market value, and revenue from $93 million in 2013 to 2022. The market capitalization has grown at an average annual rate of 57%, and the revenue has grown from $93 million in 2013 to $5.2 billion in the third quarter of 2022, a 50-fold increase in revenue, while the net income has grown from $04 million to $990 million. With the application of different strategies, Taishin Health has been able to gain a foothold in the CDMO (Contract Development and Manufacturing Organization) industry, and at the same time, we have continued to work with our customers' R&D strategies, improve our own production capabilities, and continuously develop new technologies. CDMO has gradually expanded from CDMO to CRDMO (Contract Research, Development and Manufacturing Organization), and is becoming a truly extended and indispensable part of the pharmaceutical industry chain.
    描述: 碩士
    指導教授:蕭育仁
    委員:蕭育仁
    委員:周冠男
    委員:陳炳全
    資料類型: thesis
    顯示於類別:[生物科技高階管理碩士專班] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML88檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋